Unknown

Dataset Information

0

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.


ABSTRACT: Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

SUBMITTER: Loibl S 

PROVIDER: S-EPMC9482917 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant  ...[more]

Similar Datasets

| S-EPMC7755445 | biostudies-literature
| S-EPMC10102844 | biostudies-literature
| S-EPMC7317721 | biostudies-literature
| S-EPMC5125250 | biostudies-literature
| S-EPMC4313867 | biostudies-literature
| S-EPMC4876844 | biostudies-literature
| S-EPMC4207068 | biostudies-literature
| S-EPMC3268553 | biostudies-literature
| S-EPMC9500475 | biostudies-literature
| S-EPMC11462951 | biostudies-literature